A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Registration Number
- NCT04182204
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study comprises of two stages: a safety run-in stage and a randomized controlled trial (RCT).
- Detailed Description
The safety run-in stage (Stage 1) will assess the safety of polatuzumab vedotin plus rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) in 10 participants. The randomized controlled trial (RCT) (Stage 2) will compare Pola-R-GemOx versus R-GemOx alone using overall survival (OS). This is an event-driven trial.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 270
- Histologically-confirmed diffuse large B-cell lymphoma, not otherwise specified (NOS) or history of transformation of indolent disease to DLBCL
- Relapsed disease (disease that has recurred following a response that lasted ≥ 6 months from completion of the last line of therapy) or refractory disease (disease that did not respond to or that progressed during therapy or progressed within 6 months (< 6 months) of prior therapy)
- At least one (≥ 1) line of prior systemic therapy:
- Patients may have undergone autologous hematopoietic stem cell transplantation (HSCT) prior to recruitment; In such cases, salvage chemotherapy (e.g., rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP] and rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE]) will be counted as one line of therapy and conditioning chemotherapy (e.g., BEAM) followed by consolidative autologous HSCT will be counted as one line of therapy
- Patients may have undergone allogeneic HSCT prior to recruitment, so long as they are off all immunosuppressive therapy and have no active GVHD; In such cases, salvage chemotherapy (e.g., R-DHAP and R-ICE) will be counted as one line of therapy and conditioning chemotherapy (e.g., carmustine, etoposide, cytarabine, and melphalan [BEAM]) followed by allogeneic HSCT will be counted as a separate line of therapy
- Participants may have undergone CAR T-cell therapy prior to recruitment. In such cases, cell collection, conditioning chemotherapy, and infusion will be counted as one line of therapy.
- Local therapies (e.g., radiotherapy) will not be considered as lines of treatment
- For participants with a history of the transformation of indolent disease to DLBCL, it is preferred that participants have received at least one treatment for the transformed lymphoma. However, if there are cases where the participants have received an anthracycline-containing chemotherapy regimen (such as R-CHOP) for the indolent lymphoma only, then these participants can be considered as eligible.
- At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest dimension as measured by CT or MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
- Adequate hematological function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm,
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
- Contraindication to rituximab, gemcitabine or oxaliplatin
- Peripheral neuropathy assessed to be > Grade 1 according to NCI CTCAE v5.0
- Prior use of polatuzumab vedotin or a gemcitabine plus platinum-based agent combination, recent participation in a clinical trial, and/or treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy within 2 weeks
- Planned autologous or allogenic stem cell transplantation or CAR T-cell therapy at time of recruitment
- Primary or secondary central nervous system (CNS) lymphoma
- Richter's transformation or prior CLL
- Abnormal laboratory values or health conditions, as assessed by the investigator, any known conditions preventing adherence to protocol or active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
- Vaccination with a live vaccine within 4 weeks prior to treatment
- Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1) other than for diagnosis
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 12 months after the last dose of study drug
- Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pola-R-GemOx (Stage 1) Polatuzumab Vedotin Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 1) Rituximab Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 1) Oxaliplatin Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 1) Gemcitabine Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 2) Polatuzumab Vedotin Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 2) Oxaliplatin Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 2) Rituximab Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. Pola-R-GemOx (Stage 2) Gemcitabine Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. R-GemOx (Stage 2) Rituximab Participants will receive rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. R-GemOx (Stage 2) Gemcitabine Participants will receive rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration. R-GemOx (Stage 2) Oxaliplatin Participants will receive rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
- Primary Outcome Measures
Name Time Method Stage 1: Percentage of Participants with Adverse Events (AEs) From baseline until 90 days after last dose (up to approximately 55 months) Stage 2: Overall Survival (OS) From randomization in RCT up to approximately 34 months Overall survival was defined as the time from the date of randomization to the date of death from any cause.
- Secondary Outcome Measures
Name Time Method Stage 1: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin Post-Baseline Baseline up until Month 2 of the Post-Treatment Follow-up period (up to approx. 55 months) Stage 1: Best Overall Response (BOR) From baseline up to approximately 71 months BOR is defined as the best response recorded from the start of treatment until end of treatment (based on PET-CT or CT data) according to Lugano 2014 response criteria, determined by the investigator
Stage 2: Percentage of Participants with Objective Response (OR) From randomization in RCT until up to 34 months OR is defined as CR or PR and will be assessed by an Independent review committee through PET-CT scan according to Lugano 2014 response criteria.
OR will also be assessed by the investigator using Response alone (not including PET data) and will consider complete response instead of complete metabolic response.Stage 1: Percentage of Participants with Polatuzumab Vedotin Dose Interruptions and Dose Reductions From baseline up to approx. 55 months Stage 1: Percentage of Participants with Complete Response (CR) From baseline up to approximately 55 months CR was defined as complete metabolic response assessed by the investigator through PET-CT Scan according to Lugano 2014 response criteria.
Stage 1: Percentage of Participants with Objective Response (OR) From baseline up to approximately 55 months OR is defined as complete metabolic response (CR) or partial metabolic response (PR) and will be assessed by the investigator through PET-CT scan according to Lugano 2014 response criteria.
Stage 2: Percentage of Participants with Complete Response (CR) From randomization in RCT until up to 34 months CR will be assessed by an Independent review committee through PET-CT scan according to Lugano 2014 response criteria.
CR will also be assessed by the Investigator using Response (not including PET data) and will consider complete response instead of complete metabolic response.Stage 1: Polatuzumab Vedotin Dose Intensity From baseline up to approx. 55 months Dose intensity is defined as the ratio of actual dose administered versus intended dose.
Stage 1: Progression Free Survival (PFS) From baseline up to approximately 71 months PFS is defined as the time from enrollment to the first occurrence of disease progression (as determined by the investigator according to Lugano 2014 response criteria) or death.
Stage 2: Progression Free Survival (PFS) From randomization in RCT until up to 49 months PFS is defined as the time from the time of randomization to the first occurrence of disease progression (as determined by the investigator according to Lugano 2014 response criteria) or death.
Stage 1: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin at Baseline Baseline (Day 1 of Stage 1) Stage 2: Duration of Response (DOR) From randomization in RCT until up to 49 months DOR will be assessed in patients who had an OR, as determined by the investigator, using Lugano 2014 response criteria. DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first.
Stage 2: Time to Deterioration in Physical Functioning and Fatigue Baseline (Cycle 1 [each cycle is 21 days]), Cycles 2, 3, 5, and 7; 28 days after last dose; and every 2 months during follow up (up to 49 months) Time to deterioration in physical functioning and fatigue is defined as the time from randomization to the first documentation of a 10-point decrease in EORTC QLQ-C30 physical functioning and fatigue scales from baseline. The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.
Stage 2: Percentage of Participants with Polatuzumab Vedotin Dose Interruptions and Dose Reductions From baseline in RCT up to approx. 34 months Stage 2: Event Free Survival (EFS) From randomization in RCT until up to 49 months EFS is defined as the time from enrollment to the first occurrence of disease progression or relapse, death due to any cause or initiation of NALT.
Stage 1: Percentage of Participants with Peripheral Neuropathy From baseline up to approximately 71 months Peripheral neuropathy will be measured by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12-Item Scale (FACT-GOG/Ntx12). FACT-GOG/Ntx12 is a 12-item self-reported questionnaire designed to measure chemotherapy-induced peripheral neuropathy and contains 12 items, covering sensory neuropathy, motor neuropathy, hearing neuropathy, and dysfunction associated with neuropathy.
Stage 1: Overall Survival (OS) From baseline up to approximately 71 months OS is defined as the time from enrollment to death from any cause.
Stage 1: Event Free Survival (EFS) From baseline up to approximately 71 months EFS is defined as the time from enrollment to the first occurrence of disease progression or relapse, death due to any cause or initiation of any non-protocol-specified antilymphoma treatment (NALT).
Stage 2: Best Overall Response (BOR) From randomization in RCT until up to 49 months BOR is defined as the best response recorded from the start of treatment until end of treatment (based on PET-CT or CT data) according to Lugano 2014 response criteria, determined by the investigator
Stage 2: Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score Baseline (Cycle 1 [each cycle is 21 days]), Cycles 2, 3, 5, and 7; 28 days after last dose; and every 2 months during follow up (up to 49 months) The FACT-Lym is a validated health-related quality of life (HRQoL) instrument used specifically in patients with lymphoma. It is composed of the 27-item FACT-general questionnaire (FACT-G), which measures health-related quality of life in patients undergoing any type of cancer therapy, plus the 15-item Lymphoma-Specific Subscale (FACT-Lym LYMS), which assesses the HRQoL impacts of more lymphoma-specific symptoms. Each item of the FACT-Lym is answered using a 5-point scale ranging from 0 = "not at all" to 4 = "very much". 0 = Not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = Very much. FACT-LYM total score can be calculated and higher scores are reflective of better HRQoL.
Stage 2: Time to Progression in Lymphoma Symptoms According to FACT-Lym Subscale Baseline (Cycle 1 [each cycle is 21 days]), Cycles 2, 3, 5, and 7; 28 days after last dose; and every 2 months during follow up (up to 49 months) Time to progression is defined as the time from randomization to the first documentation of a 3-point decrease (clinically meaningful change) from baseline.
Stage 2: Change from Baseline in Peripheral Neuropathy According to FACT/GOG-NTX-12 Subscale Score Baseline (Cycle 1 [each cycle is 21 days]), Cycles 2, 3, 5, and 7; 28 days after last dose; and every 2 months during follow up (up to 49 months) FACT/GOG-Ntx12 is a 12-item self-reported questionnaire designed to measure chemotherapy-induced peripheral neuropathy and contains 12 items, covering sensory neuropathy, motor neuropathy, hearing neuropathy, and dysfunction associated with neuropathy. It is answered using a 5-point scale ranging from 0 = "not at all" to 4 = "very much". 0 = Not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = Very much. FACT/GOG-Ntx12 subscale scores can be calculated with higher scores reflective of a better outcome.
Stage 2: Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score Baseline (Cycle 1 [each cycle is 21 days]), Cycles 2, 3, 5, and 7; 28 days after last dose; and every 2 months during follow up (up to 49 months) The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.
Stage 2: Percentage of Participants with Adverse Events (AEs) From randomization in RCT until up to 34 months Stage 2: Percentage of Participants with Peripheral Neuropathy From randomization in RCT until up to 49 months Peripheral neuropathy will be measured by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12-Item Scale (FACT-GOG/Ntx12). FACT-GOG/Ntx12 is a 12-item self-reported questionnaire designed to measure chemotherapy-induced peripheral neuropathy and contains 12 items, covering sensory neuropathy, motor neuropathy, hearing neuropathy, and dysfunction associated with neuropathy.
Stage 2: Polatuzumab Vedotin Dose Intensity From baseline in RCT up to approx. 34 months Dose intensity is defined as the ratio of actual dose administered versus intended dose.
Stage 2: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin at Baseline Baseline (Day 1 of Stage 2) Stage 2: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin Post-Baseline Baseline (Day 1 of Stage 2) up until Month 2 of the Post-Treatment Follow-up period (up to approx. 34 months)
Trial Locations
- Locations (67)
Istanbul Uni Istanbul Medical Faculty
🇹🇷Istanbul, Turkey
MSKCC at Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
USL 4 di Prato - Nuovo Ospeale di Prato
🇮🇹Prato, Toscana, Italy
Memorial Sloan Kettering - Monmouth
🇺🇸Middletown, New Jersey, United States
Liga Norte Riograndense Contra O Câncer
🇧🇷Natal, Rio Grande Do Norte, Brazil
Hospital das Clinicas - FMUSP
🇧🇷Sao Paulo, São Paulo, Brazil
All India Institute of Medical Sciences ,Institute Rotary Cancer Hospital
🇮🇳New Delhi, Delhi, India
Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Tata Medical Center
🇮🇳Kolkata, WEST Bengal, India
St James' Hospital
🇮🇪Dublin, Ireland
Azienda Ospedaliero-Universitaria Policlinico di Modena Ematologia
🇮🇹Modena, Emilia-Romagna, Italy
Az. Osp. Uni Ria Policlinico Tor Vergata
🇮🇹Roma, Lazio, Italy
Uni Degli Studi Di Bari, Policlinico
🇮🇹Bari, Puglia, Italy
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
Gyeongsang National University Hospital
🇰🇷Gyeongsangnam-do, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Health Pharma Professional Research
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Hospital de Especialidades Centro Medico Nacional La Raza
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Instituto Nacional de Cancerologia
🇲🇽Distrito Federal, Mexico
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
London Health Sciences Centre
🇨🇦London, Ontario, Canada
Niagara Health Systems - St. Catherines General Site
🇨🇦St. Catharines, Ontario, Canada
Hospital Universitario de Canarias
🇪🇸La Laguna, Tenerife, Spain
Hospital Universitario Dr. Peset
🇪🇸Valencia, Spain
Sakarya Universitesi Egitim ve Arastirma Hastanesi
🇹🇷Adapazari/Sakarya, Turkey
Hospital Univ. 12 de Octubre
🇪🇸Madrid, Spain
McGill University Health Centre - Glen Site
🇨🇦Montreal, Quebec, Canada
Centre hospitalier regional de Trois-Rivieres
🇨🇦Trois-Rivieres, Quebec, Canada
Hu Nan Provincial Cancer Hospital
🇨🇳Changsha, China
Cancer Center, Sun Yat-sen University of Medical Sciences
🇨🇳Guangzhou, China
West China Hospital - Sichuan University
🇨🇳Chengdu, China
Guangxi Cancer Hospital of Guangxi Medical University
🇨🇳Nanning, China
The 1st Affiliated Hospital of Nanchang Unversity
🇨🇳Nanchang, China
Institute of Hematology and Hospital of Blood Disease
🇨🇳Tianjin City, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, China
Hospital Clinico Universitario de Salamanca
🇪🇸Salamanca, Spain
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
🇨🇳Xi'an, China
Oulu University Hospital
🇫🇮Oulu, Finland
Abdurrahman Yurtarslan Onkoloji Training and Research Hospital
🇹🇷Ankara, Turkey
Akdeniz Uni School of Medicine
🇹🇷Antalya, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Kocaeli Universitesi Tip Fakultesi
🇹🇷Kocaeli, Turkey
Amerikan HAstanesi Onkoloji Birimi Te?vikiye
🇹🇷Ni?anta??, Turkey
Tampere University Hospital
🇫🇮Tampere, Finland
Hopital Henri Mondor
🇫🇷Creteil, France
CHU de Nîmes - Hôpital Carémeau
🇫🇷Nimes, France
Hopital De Haut Leveque
🇫🇷Pessac, France
Centre Henri Becquerel
🇫🇷Rouen, France
ICANS
🇫🇷Strasbourg, France
Hopital Bretonneau
🇫🇷Tours, France
Universitätsklinikum Ulm
🇩🇪Ulm, Germany
Laiko General Hospital
🇬🇷Athens, Greece
Attiko Hospital
🇬🇷Athens, Greece
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Kings College Hospital
🇬🇧London, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
Cancer Specialists
🇺🇸Jacksonville, Florida, United States
IHA Hematology Oncology Consultants - Ann Arbor
🇺🇸Ann Arbor, Michigan, United States
Memorial Sloan Kettering Cancer Center at Bergen
🇺🇸Montvale, New Jersey, United States
MSKCC @ Commack
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Nassau
🇺🇸Uniondale, New York, United States
Hospital Sao Rafael - HSR
🇧🇷Salvador, Bahia, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Memorial Cancer Institute at Memorial West
🇺🇸Pembroke Pines, Florida, United States
Memorial Sloan Kettering Cancer Center at Westchester
🇺🇸Harrison, New York, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States